Theravance Biopharma, Inc. Revenue
Theravance Biopharma, Inc. (TBPH) reported Revenue of $20.73 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-11
- Theravance Biopharma, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $20.73M, a 20.86% decline year-over-year.
- Theravance Biopharma, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $17.70M, a 15.02% increase year-over-year.
- Theravance Biopharma, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $45.89M, a 144.70% increase year-over-year.
- Theravance Biopharma, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $19.99M, a 18.51% increase year-over-year.
- Theravance Biopharma, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2025 was $107.46M, a 66.92% increase from fiscal 2024.
- Theravance Biopharma, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $64.38M, a 12.12% increase from fiscal 2023.
- Theravance Biopharma, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $57.42M, a 11.84% increase from fiscal 2022.
- Theravance Biopharma, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2022 was $51.35M, a 7.17% decline from fiscal 2021.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $20.73M 10-Q · filed 2026-08-11 | $38.43M 10-Q · filed 2026-08-11 | $84.32M derived: sum of 3 quarters · filed 2026-08-11 | $104.31M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $17.70M 10-Q · filed 2026-05-07 | $63.59M derived: sum of 2 quarters · filed 2026-05-07 | $83.58M derived: sum of 3 quarters · filed 2026-05-07 | $109.78M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $45.89M 10-K · filed 2026-03-23 | $65.88M derived: sum of 2 quarters · filed 2026-03-23 | $92.08M derived: sum of 3 quarters · filed 2026-08-11 | $107.46M 10-K · filed 2026-03-23 |
| 2025-09-30 | $19.99M 10-K · filed 2026-03-23 | $46.19M derived: sum of 2 quarters · filed 2026-08-11 | $61.57M 10-Q · filed 2025-11-12 | $80.33M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $26.20M 10-Q · filed 2026-08-11 | $41.58M 10-Q · filed 2026-08-11 | $60.34M derived: sum of 3 quarters · filed 2026-08-11 | $77.20M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $15.39M 10-Q · filed 2026-05-07 | $34.14M derived: sum of 2 quarters · filed 2026-05-07 | $51.01M derived: sum of 3 quarters · filed 2026-05-07 | $65.27M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $18.75M 10-K · filed 2026-03-23 | $35.62M derived: sum of 2 quarters · filed 2026-03-23 | $49.88M derived: sum of 3 quarters · filed 2026-03-23 | $64.38M 10-K · filed 2026-03-23 |
| 2024-09-30 | $16.87M 10-K · filed 2026-03-23 | $31.12M derived: sum of 2 quarters · filed 2026-03-23 | $45.63M 10-Q · filed 2025-11-12 | $63.19M derived: sum of 4 quarters · filed 2026-03-23 |
| 2024-06-30 | $14.26M 10-K · filed 2026-03-23 | $28.76M 10-Q · filed 2025-08-13 | $46.32M derived: sum of 3 quarters · filed 2026-03-23 | $62.02M derived: sum of 4 quarters · filed 2026-03-23 |
| 2024-03-31 | $14.50M 10-K · filed 2026-03-23 | $32.07M derived: sum of 2 quarters · filed 2026-03-23 | $47.76M derived: sum of 3 quarters · filed 2026-03-23 | $61.51M derived: sum of 4 quarters · filed 2026-03-23 |
| 2023-12-31 | $17.57M 10-K · filed 2025-03-07 | $33.26M derived: sum of 2 quarters · filed 2025-03-07 | $47.01M derived: sum of 3 quarters · filed 2025-03-07 | $57.42M 10-K · filed 2025-03-07 |
| 2023-09-30 | $15.69M 10-K · filed 2025-03-07 | $29.44M derived: sum of 2 quarters · filed 2025-03-07 | $39.86M 10-Q · filed 2024-11-14 | $54.51M derived: sum of 4 quarters · filed 2025-03-07 |
| 2023-06-30 | $13.75M 10-K · filed 2025-03-07 | $24.17M 10-Q · filed 2024-08-08 | $38.81M derived: sum of 3 quarters · filed 2025-03-07 | $51.27M derived: sum of 4 quarters · filed 2025-03-07 |
| 2023-03-31 | $10.42M 10-K · filed 2025-03-07 | $25.07M derived: sum of 2 quarters · filed 2025-03-07 | $37.52M derived: sum of 3 quarters · filed 2025-03-07 | $48.57M derived: sum of 4 quarters · filed 2025-03-07 |
| 2022-12-31 | $14.65M 10-K · filed 2024-03-01 | $27.10M derived: sum of 2 quarters · filed 2024-03-01 | $38.15M derived: sum of 3 quarters · filed 2024-03-01 | $51.35M 10-K · filed 2024-03-01 |
| 2022-09-30 | $12.45M 10-K · filed 2024-03-01 | $23.50M derived: sum of 2 quarters · filed 2024-03-01 | $36.70M 10-Q · filed 2023-11-09 | $51.64M derived: sum of 4 quarters · filed 2024-03-01 |
| 2022-06-30 | $11.05M 10-K · filed 2024-03-01 | $24.25M 10-Q · filed 2023-08-09 | $39.19M derived: sum of 3 quarters · filed 2024-03-01 | $52.39M derived: sum of 4 quarters · filed 2024-03-01 |
| 2022-03-31 | $13.20M 10-K · filed 2024-03-01 | $28.14M derived: sum of 2 quarters · filed 2024-03-01 | $41.34M derived: sum of 3 quarters · filed 2024-03-01 | $54.25M derived: sum of 4 quarters · filed 2024-03-01 |
| 2021-12-31 | $14.95M 10-K · filed 2023-03-01 | $28.14M derived: sum of 2 quarters · filed 2023-03-01 | $41.05M derived: sum of 3 quarters · filed 2023-03-01 | $55.31M 10-K · filed 2023-03-01 |
| 2021-09-30 | $13.19M 10-K · filed 2023-03-01 | $26.11M derived: sum of 2 quarters · filed 2023-03-01 | $40.37M 10-Q · filed 2022-11-09 | $59.09M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-06-30 | $12.91M 10-K · filed 2023-03-01 | $27.17M 10-Q · filed 2022-08-08 | $45.90M derived: sum of 3 quarters · filed 2023-03-01 | $64.16M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-03-31 | $14.26M 10-K · filed 2023-03-01 | $32.99M derived: sum of 2 quarters · filed 2023-03-01 | $51.24M derived: sum of 3 quarters · filed 2023-03-01 | $66.25M derived: sum of 4 quarters · filed 2023-03-01 |
| 2020-12-31 | $18.73M 10-K · filed 2022-02-28 | $36.99M derived: sum of 2 quarters · filed 2022-02-28 | $51.99M derived: sum of 3 quarters · filed 2022-02-28 | $71.86M 10-K · filed 2023-03-01 |
| 2020-09-30 | $18.26M 10-K · filed 2022-02-28 | $33.27M derived: sum of 2 quarters · filed 2022-02-28 | $53.13M 10-Q · filed 2021-11-08 | $82.63M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $15.01M 10-K · filed 2022-02-28 | $34.87M 10-Q · filed 2021-08-05 | $64.37M derived: sum of 3 quarters · filed 2022-02-28 | $76.80M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $19.86M 10-K · filed 2022-02-28 | $49.36M derived: sum of 2 quarters · filed 2022-02-28 | $61.79M derived: sum of 3 quarters · filed 2022-02-28 | $87.94M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | $29.50M 10-K · filed 2021-02-26 | $41.93M derived: sum of 2 quarters · filed 2021-02-26 | $68.08M derived: sum of 3 quarters · filed 2021-02-26 | $73.41M 10-K · filed 2022-02-28 |
| 2019-09-30 | $12.43M 10-K · filed 2021-02-26 | $38.58M derived: sum of 2 quarters · filed 2021-02-26 | $43.91M 10-Q · filed 2020-11-09 | $59.65M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-06-30 | $26.15M 10-K · filed 2021-02-26 | $31.49M 10-Q · filed 2020-08-10 | $47.23M derived: sum of 3 quarters · filed 2021-02-26 | $60.06M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-03-31 | $5.34M 10-K · filed 2021-02-26 | $21.07M derived: sum of 2 quarters · filed 2021-02-26 | $33.91M derived: sum of 3 quarters · filed 2021-02-26 | $57.39M derived: sum of 4 quarters · filed 2021-02-26 |
| 2018-12-31 | $15.74M 10-K · filed 2020-02-27 | $28.57M derived: sum of 2 quarters · filed 2020-02-27 | $52.05M derived: sum of 3 quarters · filed 2020-02-27 | $60.37M 10-K · filed 2021-02-26 |
| 2018-09-30 | $12.84M 10-K · filed 2020-02-27 | $36.31M derived: sum of 2 quarters · filed 2020-02-27 | $44.63M 10-Q · filed 2019-11-08 | $49.15M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-06-30 | $23.48M 10-K · filed 2020-02-27 | $31.80M 10-Q · filed 2019-08-05 | $36.31M derived: sum of 3 quarters · filed 2020-02-27 | $40.59M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-03-31 | $8.32M 10-K · filed 2020-02-27 | $12.83M derived: sum of 2 quarters · filed 2020-02-27 | $17.11M derived: sum of 3 quarters · filed 2020-02-27 | $20.62M derived: sum of 4 quarters · filed 2020-02-27 |
| 2017-12-31 | $4.51M 10-K · filed 2019-02-28 | $8.79M derived: sum of 2 quarters · filed 2019-02-28 | $12.30M derived: sum of 3 quarters · filed 2019-02-28 | $15.39M 10-K · filed 2020-02-27 |
| 2017-09-30 | $4.28M 10-K · filed 2019-02-28 | $7.78M derived: sum of 2 quarters · filed 2019-02-28 | $10.87M 10-Q · filed 2018-11-08 | |
| 2017-06-30 | $3.51M 10-K · filed 2019-02-28 | $6.60M 10-Q · filed 2018-08-02 | ||
| 2017-03-31 | $3.09M 10-K · filed 2019-02-28 | |||
| 2016-12-31 | $48.65M 10-K · filed 2019-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |